Degeneration of synapses in Alzheimer's disease (AD) strongly correlates with cognitive 52 decline, and synaptic pathology contributes to disease pathophysiology. We recently 53 discovered that the strongest genetic risk factor for sporadic AD, apolipoprotein E epsilon 4 54 (APOE4), exacerbates synapse loss and synaptic accumulation of oligomeric amyloid beta in 55 human AD brain. To begin to understand the molecular cascades involved in synapse loss in 56 AD and how this is mediated by APOE, and to generate a resource of knowledge of changes 57 in the synaptic proteome in AD, we conducted a proteomic screen and systematic in-silico 58 analysis of synaptoneurosome preparations from temporal and occipital cortices of human 59 AD and control subjects with known APOE gene status. Our analysis identified over 5,500 60 proteins in human synaptoneurosomes and highlighted disease, brain region, and APOE-61 associated changes in multiple molecular pathways including a decreased abundance in AD 62 of proteins important for synaptic and mitochondrial function and an increased abundance of 63 proteins involved in neuroimmune interactions and intracellular signaling. 64 65
people are living with dementia worldwide, it costs over $800 billion per year to care for 68 them, and there are currently no disease modifying treatments 1 . One of the barriers to 69 developing effective therapies for Alzheimer's disease, the most common cause of dementia, 70 lies in the lack of a comprehensive understanding of the brain changes that cause 71 neurodegeneration. Extracellular amyloid beta (Aβ) plaques, intracellular neurofibrillary 72 tangles composed of hyperphosphorylated tau protein, and severe brain atrophy are the major 73 neuropathological hallmarks of AD 2 . There are many genetic risk factors for developing 74 sporadic AD, the strongest of which is inheritance of the apolipoprotein E epsilon 4 allele 75 (APOE4). Inheritance of one copy of APOE4 is associated with a 3 fold increase in disease 76 risk and inheritance of two copies with an over 10 fold increased risk 3 . In addition to its 77 known roles in Aβ production and clearance, we have observed that apoE protein is involved 78 in Aβ-mediated synapse degeneration 4, 5 , which is important as synapse loss is the strongest 79 pathological correlate with cognitive decline in AD 6, 7, 8 . ApoE4 causes more synaptic loss 80 around plaques when expressed in mouse models of familial AD 4 . Using high resolution 81 imaging in human post-mortem brain tissue, we similarly observed exacerbated synapse loss 82 in APOE4 carriers and further that apoE4 is associated with more accumulation of oligomeric 83
Aß at synapses 5 . More recent data implicates APOE4 in tau mediated neurodegeneration 9 84 and also inflammatory TREM2 mediated microglial phenotypes 10 , which may be important 85 for synapse degeneration. 86
87
Recent data from postnatal human brain samples shows that proteomic datasets can reveal 88 differences in proteins that are not observed in RNA expression data, arguing the importance 89 of building strong resource datasets at the level of protein in human diseases 11 . Thus far there 90 have been several proteomic studies of human AD brain tissue (supplemental table 1), but a 91 comprehensive dataset on human synaptic proteins examining the downstream molecular 92 effects of APOE genotype in AD remains unavailable. 93
94
In order to further our understanding of how APOE may be influencing synaptic vulnerability 95 in AD, we have performed a comprehensive proteomic study of human post-mortem brain 96 tissue through a series of molecular comparisons allowing us to assess the relative 97 contribution of both regional vulnerability and APOE variants to AD pathogenesis. Although 98 our study is in postmortem tissue which has inherent limitations including looking at a 99 snapshot of the end stage of the disease, the inclusion of a less affected brain region allows 100 some novel insight into changes that may be occurring in synapses earlier in the degenerative 101 process. We provide a unique proteomic resource identifying over 5,500 proteins in human 102 synaptoneurosome preparations. Additionally, we highlight multiple proteins and molecular 103 pathways that are modified in AD with brain region and APOE genotype status. In silico 104 analysis reveals that proteins involved in glutamatergic synaptic signalling and synaptic 105 plasticity are decreased in AD with temporal cortex (which has high levels of pathology) 106 131 Synaptic preparations were prepared and quality control for post-mortem protein degradation 141 were confirmed as previously described 12, 13, 14 (Supplementary Figure 1 for example total  142 protein stains and western blotting). Any synaptoneurosome preparations containing nuclear 143 histone protein were discarded and fresh preparations made from the same case. Protein 144 degradation was assessed using the "HUSPIR" ratio or degradation index 15 . To find this 145 value, synaptoneurosmes run on western blot were probed using an antibody against 146 NMDAR2B which recognizes two bands, the full-length protein at 170 kDa and a 147 degradation product at 150kDa. This degradation only occurs post-mortem as it is not found 148 in biopsy tissue thus comparing these two bands is an accepted indication of post mortem 149 synaptic protein degradation. Having confirmed that the extracted protein is of appropriate quality, we then applied a 160 comprehensive workflow to enable us to assess (at the protein level) the relative contribution 161 of both regional vulnerability and APOE variants as a risk factors to AD pathogenesis ( Figure  162 1C, Figure 2) 12, 13 . We performed a complex 8-plex TMT LC-MS/MS analysis. 163
Representative pools based on the outlined groupings were generated from these synaptic 164 protein extracts. By pooling individual samples according to APOE genotype and cortical 165 area, we were able to reduce potential noise in the system generated through inter individual 166 differences, subtle post mortem handling differences and/or sample isolation 16 . Thus, 25 μg 167 of each of the 34 subjects were pooled according to disease status, APOE genotype (3/3 or 168 3/4) and brain region (BA41/42 or BA17). The inclusion of an equivalent proportion of each 169 protein isolate into a readily comparable pool allowed the generation of a molecular 170 fingerprint representative of each condition and enables subsequent analysis of individual 171 patient variability in the resulting validatory work (as a deviation from the population signal, 172 as previously described 14, 17 (Fig. 3C ). After applying these further two data 206 filtering steps we obtained a set of 1532 protein IDs identified with high confidence and 207 meeting our differential abundance criteria ( Figure 3C ). 208
209
In-silico analysis revealed differences in abundance ratios correlating with increasing 210 vulnerability for AD neuropathology 211
To determine potential differences in the synaptic proteomes of AD patients vs. control 212 subjects dependent on APOE genotype and brain region, we focused on the protein 213 abundance ratios as calculated by dividing values from AD patients by matched control 214 subjects, subcategorised for APOE3/4 or APOE3/3 genotype, and segregated by brain region 215 (Fig. 3A-C Our previous work examining synapses in human post-mortem tissue has revealed that the 237 handling of the body and the tissue is critical for maintaining structural and molecular 238 integrity of synapses 20, 21 . In particular, we observe that rapid cooling of the body after death 239 preserves synapse structure and molecular integrity better even than short post-mortem 240 intervals. Therefore in this study we used samples only from the Edinburgh MRC Sudden 241 Death Brain Bank whose robust handling protocol is carried out on each individual ensuring 242 that the data is as comparable as possible. This precluded precise age and sex matching of 243 our control groups with APOE3/3 and APOE3/4 genotypes (see table 1), which could mean 244 that there are confounding effects of age and sex on our AD/control comparisons. However, 245 when we compare BA41/42 of the AD APOE3/4 to AD APOE3/3 cases, which are 246 reasonably age and sex matched, we observe many of the same pathways increased in AD 247
APOE4 carriers compared to AD APOE3 carriers as those we observed in the comparison of 248 AD vs control APOE4 carriers (Fig. 4D ). Less changes were observed in BA17 from AD 249 APOE4 carriers compared to AD APOE3 carriers. This strongly supports our conclusion that 250 APOE4 influences the synaptic proteome in AD in a region-specific manner. Interestingly, in 251 non-demented controls when APOE4 carriers are compared to APOE3 carriers in BA41/42, 252 there are changes in the opposite direction to those that are observed in E4 AD vs control. To further examine trends in protein changes in an unbiased manner, we performed clustering 278 analysis to detect differences in the abundance ratios across these differentially vulnerable 279 synaptic populations. Proteins were clustered according to their abundance profile across the 280 four calculated ratios (Fig. 4) . Each sphere represents an individual protein ID and the 281 distances between the spheres indicate the similarity in abundance profile. Different colours 282 are used to group proteins together in clusters based on abundance profile similarity. In order 283 to analyse the impact/influence of APOE genotype and cortical region, we focused 284 specifically on clusters showing a steady increase or decrease in protein abundance across the 285 four groups or only demonstrating differences in protein abundance in APOE-ε3/4 carriers in 286 BA41/42 (Fig. 4) . In order to determine if these abundance profile specific clusters were 287 associated with specific pathways and/or canonical cascades, we have carried out a higher 288 order functional clustering analysis using IPA software. IPA pathway analysis and DAVID 289 enrichment analysis highlighted multiple affected pathways. In clusters 4, 5, 8 and 21 which 290 have progressive decreases in AD/control ratios as pathological severity increases (Fig 4) , we 291 observe pathways involved in synaptic function are decreased including glutamate signalling, 292 synaptic long term potentiation, GABA receptor signalling, CREB signalling, and synaptic 293 long-term depression. Cluster 6 containing proteins that were sharply decreased in the 294 condition with most pathology, AD APOE4 BA41/42, similarly showed decreases in 295 pathways involved in synaptic function including CREB signalling and GABA receptor 296 signalling, along with decreases in pathways implicated in mitochondrial function including 297 oxidative phosphorylation (Fig 4) . Interestingly, when examining clusters 7, 9, and 18 which were progressively increased with 313 pathological vulnerability, we observe proteins involved in autophagy and chemokine 314 signalling were progressively upregulated in conditions of higher synaptic vulnerability (Fig  315   4,) . Clusters 1 and 2, which included proteins highly upregulated in AD APOE4 BA41/42 316 compared to the other groups indicate increases in pathways involved in actin cytoskeleton 317 signalling, NRF2 mediated oxidative stress response, PDGF signalling, and insulin receptor 318 signalling, which all implicate non-neuronal contributors to synapse degeneration as has been 319 recently emphasised for AD risk by genetic studies 22 . 320 321 Along with the unbiased bioinformatic analyses, we further interrogated our proteomics 322 dataset to examine proteins of interest based on what is known about synapse degeneration in 323 AD from model systems. In addition to loss of proteins involved in synaptic function in 324 remaining synapses in AD as shown with bioinformatics, it is likely that there is some degree 325 of synaptic remodelling/compensation taking place as some synaptic proteins were increased. 326
The synaptic receptor TMEM97 is increased 2.8 fold in remaining synapses in AD vs control 327 APOE4 carriers in BA41/42 (Fig 5) . This is particularly interesting because TMEM97 is the 328 sigma 2 receptor, and compounds that disrupt interaction of Aβ and sigma 2 receptors are 329 protective in mouse models and are being tested for efficacy in human AD as a therapeutic 23 . 330 331 Recent data strongly implicate the complement cascade and microglia in Aβ mediated 332 synapse loss in mouse models of amyloid deposition 24, 25 . Two studies recently demonstrated 333 upregulation of components of the complement system in AD brain and influence of 334 complement cascade in synapse dysfunction and loss in a mouse model of tauopathy 26, 27 . 335
Based on these data, we interrogated our human synaptoneurosome dataset to look at proteins 336 important for microglial synapse phagocytosis and specifically the complement system. 337
Pathway analysis reveals increases in CD40, IL-6, IL-8, IL-1, IL-2, IL-7 and acute phase 338 response signalling, indicating neuroimmune signalling between neurons and glia in 339 synapses, which is modulated by APOE genotype (Fig 3,4, supplemental figure 3 ). In order to validate the proteomics data, we selected a subset of proteins for western blot 348 analysis in BA41/42 whose levels should be increased or decreased just past our magnitude 349 of change cutoff as this will be more indicative of the sensitivity of the MS than highly up or 350 downregulated proteins. We also selected a protein whose levels was unchanged to use as an 351 internal control (Fig 5, full blots shown in supplementary figure 3 ). proteins (SNAP25) and post-synaptic (PSD95) respectively are downregulated in the 364 synapses of AD patients. E. Abundance of alpha synuclein, a presynaptic protein that is 365 often associated with neurodegeneration, is also appreciably decreased in AD patients. F.
366
Mitochondrial protein SOD2 is unchanged in AD vs control. G. Annexin V is upregulated in 367 the synapses of AD patients. H. TMEM97, a proposed synaptic receptor for Abeta is 368 increased in AD. Total protein stained gels were used as a loading control as described in 29 . 369 Data are shown as means and standard errors with each dot representing an individual case. TMEM97 (E), beta tubulin (F), and total protein at high intensity (G) and low intensity (H). 378
Each of the molecular weight ranges in H were quantified for each lane, shown in (I). 379
Comparisons between proteomics and western blot data are shown in J. 380 381
Discussion

383
Of the pathological changes associated with dementia, the best correlate to the extent of 384 memory decline in life is the loss of synapses. Synapses are exquisitely complicated 385 structures requiring thousands of proteins for the complex process of establishing, 386 maintaining, and undergoing synaptic transmission. Work from animal models and human 387 post mortem tissue indicates that synapse degeneration is a driving force in disease 388 progression in AD. However, to date there has been a lack of data on the precise molecular 389 changes in synapses in human AD brain, which impedes the design of hypothesis driven 390 experiments to understand mechanisms of synapse degeneration in animal models that are 391 likely to be relevant to human disease. In the literature, we found 19 publications using 392 proteomics on human AD brain tissue (supplemental table 1 33 . This study used whole tissue homogenates from AD and control subjects for 398 proteomics but focused their analysis on a group of 191 proteins that had previously been 399 detected in synaptosome fractions of healthy subjects. With this method, they observed a 400 downregulation of glutamate signalling proteins and an effect of APOE4 genotype on the 401 abundance of these synaptic proteins. Our results significantly expand upon these findings as 402 we biochemically isolated synaptoneurosomes from AD and control subjects and detected 403 over 5,500 proteins, which is over 25 times more proteins examined than in the previous 404 study of synaptic proteins. Synaptoneurosome preparations have not previously been used in 405 proteomic studies of AD. Synaptoneurosomes, unlike other synaptic fractions, contain both 406 the presynaptic and postsynaptic compartments, which is important due to data from model 407 systems implicating both pre and post synapses in degenerative mechanisms. Further, the 408 preparation might retain parts of glial processes closely associated with the synapse, which is 409 key for understanding the role of non-neuronal cells in synapse degeneration, an important 410 topic in the field 22 . 411 412 We observed that multiple pathways including those associated with synaptic and 413 mitochondrial function were downregulated with increasing vulnerability and other pathways 414 including intracellular signalling and neuroimmune signalling proteins were increased with 415 increasing vulnerability. This is encouraging as dysfunctional synaptic signalling is consistent 416 with multiple lines of evidence from AD animal models 8, 34, 35 . Some of the proteins that we 417 observe are reduced in AD synapses have been observed as CSF biomarkers associating with 418 disease. For example, we observe a 25% decrease in neurexin 2 and over 30% decrease in 419 neurogranin abundance in AD APOE4 superior temporal gyrus compared to controls, 420 whereas recently published biomarker studies observed increases in neurexin 2 and 421 neurogranin in CSF of people with mild cognitive impairment or AD 36, 37, 38 . In another 422 study of CSF, a group of 9 synaptic proteins (GluR2, GluR4, Neuroligin-2, Neurexin-3A, 423
Neurexin-2A, Calsynytenin-1, Syntaxin-1B, Thy-1, and VAMP-2) were increased before 424 markers of neurodegeneration are observed 39 . Not only does this CSF data serve to further 425 highlight the veracity of the proteomic data generated here, but critically, it also supports the 426 notion that proteins may be removed from synapses and at least some of these cleared from 427 the brain via CSF. and tau have been observed in model systems to impact mitochondrial function and the 451 intracellular transport of mitochondria, which impair synaptic function 43, 44, 45 . And there is 452 some evidence that APOE4 can impair mitochondria function in cell culture . 46 However, the 453 role of APOE4 in synaptic mitochondrial function in human brain has not been studied. We 454 observe region and APOE specific changes in proteins involved oxidative phosphorylation 455 with a strong decrease in BA41/42 of AD patients that was larger in APOE4 carriers than 456 APOE3 carriers. Conversely, this pathway was increased in BA17 with the strongest 457 increase in E3 carriers. This could reflect a compensatory increase in mitochondrial function 458 in brain regions that are very early in the disease process. Consistent with the BA41/42 data, 459
we recently observed a decrease in presynaptic terminals containing multiple mitochondria in 460 the temporal cortex of AD patients 20 . 461 462 Synaptic degeneration is an important part of AD pathogenesis. Further understanding this 463 process and how to delay and/or halt it may lead us towards important novel therapeutic 464 targets not only for AD but also for other diseases for which synapse loss is an integral or 465 important process. By coupling subcellular fractionation with anatomical knowledge of 466 regional vulnerability and human patient genetics we were able to generate the most 467 comprehensive synaptic proteomics profiling datasets from human AD patient samples to 468 date. Importantly, we have determined its accuracy through experimental validation and links 469 to existing published literature on mechanisms and biomarker identification. As an example 470 of the potential utility of such data we were able to begin to uncover how AD and APOE4 471 impact synaptic composition and may be leading to synaptic degeneration. Although in this 472 discussion we have highlighted specific proteins and cascades correlating with regional 473 vulnerability and discussed their potential roles in disease progression and /or regulation this 474 was done to highlight the potential utility of our dataset. There are many other potentially 475 important proteins and pathways in these data to explore in future stidies. We have made the 476 data freely available and hope that this will provide a useful resource for other researchers in 477 the field to use at their discretion. The results described here demonstrate that APOE 478 genotype has a profound impact on the molecular fingerprint of the synapse and that further 479 understanding of the effects of these protein changes may contribute to our understanding of, 480
and ultimately the development of novel therapies for AD. were examined by a neuropathologist, and after the proteomics results were returned, it was 495 noted that one of the AD cases was neuropathologically classified as frotntotemporal 496 dementia with tau-associated corticobasal degeneration (table 1) . 497
498
APOE genotyping 499
DNA was extracted from ~25mg of cerebellum for each case using the QIAamp DNA mini 500 kit (Qiagen, Hilden, Germany), which was used as per the manufacturer's instructions. 501
Polymerase chain reaction (PCR) was performed on the extracted DNA. 10μl of 2x Master 502 mix (Promega, Madison, WI) was combined with 1μl of primer stock (20μM forward primer, 503 20μM reverse primer), 2μl of DMSO (Sigma-Aldrich, St Louis, MO), 6μl ddH 2 O and 1μl of 504 isolated DNA. The forward primer was 5'taagcttggcacggctgtccaagg3' and the reverse primer 505 5'acagaattcgccccggcctggtacactgcc3' (Figure 2.2A) . APOE ε2, APOE ε3, and APOE ε4 506 plasmids (generously donated by Dr E Hudry) were also amplified by PCR to use at as 507 reference and were treated in the same way as unknown samples throughout. PCR product 508 was digested using the restriction endonuclease HhaI (New England Biolabs, Ipswich, MA). 509
For this 0.5μl of enzyme, 2.5μl of 10x CutSmart buffer (New England Biolabs, Ipswich, MA) 510 and 2μl of ddH 2 O were added to each PCR reaction tube to give a total volume of 25μl. The 511 final volume contains 50 mM Potassium Acetate, 20 mM Tris-acetate, 10 mM Magnesium 512 Acetate, and 100 μg/ml BSA as a result of the CutSmart buffer and 10 units of HhaI. After 513 digestion incubation 5μl of 6x Blue Loading dye (Promega, Madison, WI) containing 0.4% 514 orange G, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 15% Ficoll® 400, 10mM Tris-515
HCl (pH 7.5) and 50mM EDTA (pH 8.0) was added to the the reaction tube. 14μl of this 516 mixture was then loaded onto precast 15 well Novex TBE 20% gel (Thermo Fisher Scientific, 517 Waltham, MA) using a 25µL Hamilton Syringe. The DNA were then separated by size using 518 electrophoresis for 2 hours at 200V. The gels were run in an XCell SureLock™ Mini-Cell 519 (Invitrogen, Carlsbad, CA) using Novex TBE running buffer (Thermo Fisher Scientific, 520 Waltham, MA). Bands were stained with either 2μg/ml ethidium bromide (Sigma-Aldrich, St 521 Louis, MO) or SYBR safe DNA Gel Stain (Thermo Fisher Scientific, Waltham, MA) and 522 visualized with an ultraviolet gel imaging system (Syngene, Cambridge, UK). 523
524
Amyloid beta and Tau staining in human cortical sections 525
Tissue sections were stained for amyloid beta and tau according to a previous study 47 . 526
Briefly, fresh post-mortem tissue blocks were fixed in formalin and dehydrated in an 527 ascending alcohol series. Three paraffin waxing stages were performed and 4μm thick tissue 528 sections were cut on a Leica microtome and collected on glass slides. Immunohistochemistry 529 for amyloid beta (BA4, M087201-2, Dako) and pTau (AT8, MN1020, Thermo) was 530 performed using the Novolink Polymer detection system and visualized using DAB as 531 chromogen. Images were acquired using an upright Zeiss axioImager equipped with 532
MicroBrightfield stereology software. 533 534
Synaptoneurosome preparation 535
Brain homogenates and synaptic fractions were prepared as described in Tai et al. 2012 48 . In 536 brief, ~300mg of cortical tissue was homogenized on ice in homogenization buffer (25 mM 537 HEPES pH 7.5, 120 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 2 mM CaCl 2 , protease inhibitors 538 (roche complete mini), phosphatase inhibitors (Millipore, 524629)). The homogenate was 539 filtered through 2 layers of 80μm nylon filter (Millipore, NY8002500) and saved as crude 540 homogenate. The crude homogenate was further filtered through a 5 μm filter (Millipore, 541 SLSV025NB) and centrifuged at 1000g for 5 min. The pellet was washed once, then the 542 supernatant was removed and the pellet was resuspended in in label-free buffer [100 mM 543
Tris-HCl (pH7.6) 4% (w/v) SDS] containing 1% protease cocktail inhibitor (Thermo Fisher, 544 UK). Homogenates were centrifuged at 20,000 x g for 20 minutes at 4°C with the soluble 545 fraction of each sample transferred to Lo-Bind tubes (Sigma Aldrich). Protein determination 546 using the Bicinchoninic acid assay (Pierce, UK) was carried out according to manufacturer's 547 guidelines. 548 549 SDS-PAGE and western blotting 550 SDS-PAGE and western blotting were performed as described previously 49 . Briefly, 5μg of 551 protein from synaptoneurosome fractions and molecular weight marker (Li-Cor, Cambridge, 552 UK) was loaded onto NuPAGE 4-12% Bis-Tris precast polyacrylamide 15 well gels 553 (Invitrogen, Paisley, UK). Proteins were transferred to polyvinylidene fluoride (PDVF) 554 membranes and blocked using Odyssey Blocking buffer (927-40,000, Li-Cor) diluted 1:1 in 555 PBS. Primary antibodies were incubated overnight in blocking buffer and proteins were 556 detected on an Odyssey system using 680 and 800 IR dye secondary antibodies diluted 557 1:10000 in blocking buffer (table 2 shows Preparation of the samples, quantification, and 566 bioinformatics was carried out according to standardized protocols 12, 13, 14 . 567 568 Samples were lysed in 4%SDS + 100mM tris prior to protein estimation by microBCA. Each 569 sample was then reduced with 100 mM DTT and samples then processed using the FASP 570 protocol 50 with some modifications. Samples were initially diluted 1:10 into 8M Urea and 571 buffer exchanged to remove the SDS and tris buffer, filters were then washed 3 times with 572 100 mM Tris-HCL pH 8 then another 3 times with 100 mM triethyl ammonium bicarbonate 573 (TEAB). Proteins on the filters are then digested twice at 30oc with trypsin (2 x 1ug), first 574 overnight and then for another 6h in a final volume of 200 µl prior to addition of 200ul of 575 500mM NaCl. Samples were then desalted using a SPE cartridge (Empore-C18, Agilent 576
Technologies, 7mm/3ml) and the peptides dried in a speedvac (Savant). 577 578 Desalted tryptic peptides (25µg each sample) were then dissolved in 100 µl 100 mM TEAB. 579
The different 8 TMT labels were dissolved in 41µL of anhydrous acetonitrile, and each label 580 then added to a different sample. The mixtures were incubated for 1 hour at room 581 temperature and the labelling reaction was then quenched by adding 8µL of 5% 582 hydroxylamine. Following labelling with TMT, samples were mixed, desalted using a SPE 583 cartridge (Empore-C18, Agilent Technologies, 7mm/3ml) and the peptides dried in a 584 speedvac (Savant). Samples were then dissolved in 200 μL ammonium formate (10 mM, pH 585 10) and peptides fractionated using High pH RP HPLC. A C18 Column from Waters 586 (XBridge peptide BEH, 130Å, 3.5 µm 2.1 X 150 mm, Ireland) with a guard column 587 (XBridge, C18, 3.5 µm, 2.1X10mm, Waters) are used on a Ultimate 3000 HPLC (Thermo-588 Scientific). Buffers A and B used for fractionation consists, respectively of 10 mM 589 ammonium formate in milliQ water and 10 mM ammonium formate with 90% acetonitrile, 590 both buffers were adjusted to pH 10 with ammonia. Fractions were collected using a WPS-591 3000FC auto-sampler (Thermo-Scientific) at 1 min intervals. Column and guard column were 592 equilibrated with 2% buffer B for 20 min at a constant flow rate of 0.2 ml/min. Samples (175 593 µl) were loaded onto the column at 0.2 ml/min. Peptides were eluted from the column with a 594 gradient of 2% buffer B to 5%B in 6 min then from 5% B to 60% B in 50 min. The column is 595 washed for 16 min at 100% buffer B and equilibrated at 2% buffer B for 20 min as mentioned 596 above. The fraction collection started 1 min after injection and stopped after 80 min (total of 597 80 fractions, 200 µl each). The total number of fractions concatenated was set to 20 by non-598 contiguous pooling and the content of the fractions dried and resuspended in 50 µl of 1% 599
formic acid prior to analysis by nLC-MS/MS. 600 601 Analysis of peptides was performed using a Q-Exactive-HF (Thermo Scientific) mass 602 spectrometer coupled with a UltiMate 3000 RSLCnano (Thermo Scientific) UHPLC system. 603 nLC buffers were as follows: buffer A (2% acetonitrile and 0.1% formic acid in Milli-Q 604 water (v/v)) and buffer B (80% acetonitrile and 0.08% formic acid in Milli-Q water (v/v) . 605
Aliquots of 15 μL of each sample (50ul in total) were loaded at 5 μL/min onto a trap column 606 (100 μm × 2 cm, PepMap nanoViper C18 column, 5 μm, 100 Å, Thermo Scientific) 607 equilibrated in 98% buffer A. The trap column was washed for 6 min at the same flow rate 608 and then the trap column was switched in-line with a Thermo Scientific, resolving C18 609 column (75 μm × 50 cm, PepMap RSLC C18 column, 2 μm, 100 Å). The peptides were 610 eluted from the column at a constant flow rate of 300 nl/min with a linear gradient from 95% 611 buffer A to 40% buffer B in 122 min, and then to 98% buffer B by 132 min. The column was 612 then washed with 95% buffer B for 15 min and re-equilibrated in 98% buffer A for 32 min. 613 Q-Exactive HF was used in data dependent mode. A scan cycle comprised MS1 scan (m/z 614 range from 335-1800, with a maximum ion injection time of 50 ms, a resolution of 120 000 615 and automatic gain control (AGC) value of 3x106) followed by 15 sequential dependant MS2 616 scans (with an isolation window set to 0.7 Da, resolution at 60000, maximum ion injection 617 time at 200 ms and AGC 1x105. To ensure mass accuracy, the mass spectrometer was 618 calibrated on the first day that the runs are performed. 619
620
The raw mass spectrometric data files obtained for each experiment were collated into a 621 single quantitated dataset using MaxQuant 1.6.0.16 18 and Andromeda search engine software 622 19 with enzyme specificity set to trypsin. Other parameters used were: (i) variable 623 modifications, deamidation (NQ), oxidation (M), protein N-acetylation, gln-pyro-glu; (ii) 624 fixed modifications, carbamidomethylation (C); (iii) database: uniprot-human_Sept2017 625 database; (iv) Reporterion MS2 -TMT labels: TMT8plex_Nter and TMT 8plex-Lys ; (v) 626 MS/MS tolerance: FTMS-10ppm, ITMS-0.02 Da; (vi) maximum peptide length, 6; (vii) 627 maximum missed cleavages, 2; (viii) maximum of labelled amino acids, 3; and (ix) false 628 discovery rate, 1%. Peptide ratios were calculated using 'Reporter Intensity' Data that was 629 normalised using 1/median ratio value for each identified protein group per labelled sample. 630
631
In silico analyses 632 
